TB Alliance

Shortfall in TB Research and Development Funding Persists as COVID-19 Erodes Hard-Won Gains

January 27, 2022

NEW YORK (January 27, 2022)—The 2021 G-Finder Report, released today, shows that low funding levels continue to encumber the pursuit

January 20, 2022

NEW YORK, NY (20 January 2022) — Today, TB Alliance announced that it has received funding from the United States Agency for

January 13, 2022

(BERLIN/GENEVA, 13 January 2022) – The German Federal Ministry of Education and Research (BMBF) through KfW has granted additional funding to

December 15, 2021

TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs

November 23, 2021

TBAJ-587-CL-001 is the first Phase 1 trial in humans conducted by TB Alliance through the European Regimen Accelerator for Tuberculosis

October 19, 2021

New results from operational research in Ukraine and MSF’s TB-PRACTECAL study on drug-resistant forms of tuberculosis to be presented PRETORIA

October 14, 2021

“We have seen a number of highly promising breakthroughs in tuberculosis (TB) drug development over the past few years, but

September 30, 2021

NEW YORK (Sept 30, 2021)—TB Alliance, a not-for-profit organization dedicated to development and delivery of improved regimens to fight tuberculosis

September 29, 2021

Dr. Eric Goosby, Sundar Kodiyalam, David Y. Norton, and Sangita Reddy Join Board NEW YORK (Sept 29, 2021)—TB Alliance, a

September 6, 2021

Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug NEW YORK and